Pfizer chooses danuglipron, an oral GLP-1 agonist, for obesity treatment and plans dose optimization studies in 2024.
Pfizer selects once-daily danuglipron formulation for obesity treatment, planning dose optimization studies in 2024. The drug, an oral GLP-1 receptor agonist, has demonstrated good efficacy in a twice-daily formulation and may have a competitive profile in the oral GLP-1 space. Danuglipron is still in development and requires further large-scale clinical trials to prove safety, effectiveness, and tolerability before FDA approval.
July 11, 2024
7 Articles